Previous close | 10.55 |
Open | 10.56 |
Bid | 10.33 x 1000 |
Ask | 10.36 x 400 |
Day's range | 10.32 - 10.59 |
52-week range | 9.70 - 14.57 |
Volume | |
Avg. volume | 3,037,000 |
Market cap | 3.051B |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.51 |
Earnings date | 08 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 18.75 |
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today issued its fourth annual Environmental, Social, and Governance (ESG) report. This year’s report highlights the strength of the Company’s corporate responsibility structure including increased efforts towards transparency in our environmental reporting, our deep commitment to ensu
In this article, we’re going to take a look at 13 best biotech stocks to buy under $20. To see more stocks that made the list, you can skip ahead and jump straight to the top 5 best biotech stocks to buy under $20. When it comes to investing, few industries are as exciting to […]